These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33952648)
21. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063 [TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251 [TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Jang N; Kwon HJ; Park MH; Kang SH; Bae YK Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143 [TBL] [Abstract][Full Text] [Related]
26. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression. Stenström J; Hedenfalk I; Hagerling C Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289 [TBL] [Abstract][Full Text] [Related]
27. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929 [TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. Gao ZH; Li CX; Liu M; Jiang JY BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978 [TBL] [Abstract][Full Text] [Related]
29. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer. Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102 [TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069 [TBL] [Abstract][Full Text] [Related]
31. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033 [TBL] [Abstract][Full Text] [Related]
32. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. Kwan ML; Bernard PS; Kroenke CH; Factor RE; Habel LA; Weltzien EK; Castillo A; Gunderson EP; Maxfield KS; Stijleman IJ; Langholz BM; Quesenberry CP; Kushi LH; Sweeney C; Caan BJ J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25921910 [TBL] [Abstract][Full Text] [Related]
33. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613 [TBL] [Abstract][Full Text] [Related]
34. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer. Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439 [TBL] [Abstract][Full Text] [Related]
35. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948 [TBL] [Abstract][Full Text] [Related]
36. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068 [TBL] [Abstract][Full Text] [Related]
37. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Wang K; Shen T; Siegal GP; Wei S Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ; van de Velde CJ; van Pelt GW; Kroep JR; Julien JP; Smit VT; Tollenaar RA; Mesker WE Breast Cancer Res Treat; 2013 Jun; 139(2):371-9. PubMed ID: 23709090 [TBL] [Abstract][Full Text] [Related]
39. Predictors of time to death after distant recurrence in breast cancer patients. Sopik V; Sun P; Narod SA Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050 [TBL] [Abstract][Full Text] [Related]
40. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer. Kwon MJ Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]